glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Effect of the Glucagon-Like Peptide-1 Agonists and Liraglutide on in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER flow trial semaglutide kidney outcomes
Description
In 1994, Dr
9.7% in placebo)
Funding: This work was partially supported by the National Natural Science Foundation of China (82274379), Fundamental Research Funds for the Central Universities (2022-JYB-JBZR-009), and Beijing University of Chinese Medicine High-level Talent Start-up Research Project (2021-XJ-KYQD-004)
Presentation 1-AC-SY09 (2017)
Most tolerate long-term with tweaks, achieving glycemic control and heart protection
